Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide or MEK Inhibitor + Hydroxychloroquine in RAS-Mutant Tumors
NCT06229340Phase 2Recruiting
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leflunomide, hydroxychloroquine, trametinib, cobimetinib, binimetinib in colorectal cancer (CRC), pancreatic cancer (PC), lung cancer, melanoma, solid tumor, sponsored by N.N. Petrov National Medical Research Center of Oncology. Started Oct 2023; status: recruiting.
02
Drugs
leflunomidehydroxychloroquinetrametinibcobimetinibbinimetinib
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)lung cancermelanomasolid tumor
Beyond the preview
Go deeper on NCT06229340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229340.